Literature DB >> 12798640

CD40 ligand (CD154) improves the durability of respiratory syncytial virus DNA vaccination in BALB/c mice.

Jennifer L Harcourt1, Michael P Brown, Larry J Anderson, Ralph A Tripp.   

Abstract

Respiratory syncytial virus (RSV) infection is the single most important cause of serious acute respiratory illness in children <1 year of age worldwide, and is associated with life-threatening pneumonia or bronchiolitis in the elderly. Current vaccine strategies include live, attenuated virus, subunit and DNA vaccines, however, none have been sufficiently safe, or shown to induce satisfactory long-term immunity, thus immune modulators are being considered to enhance the effectiveness of RSV vaccines. In this study, we examine CD40 ligand (CD40L) as an immune modulator to enhance the durability of DNA vaccines encoding RSV F and/or G glycoproteins in BALB/c mice. The addition of CD40L to DNA vaccines encoding the F glycoprotein enhanced virus clearance and some aspects of the immune response to RSV challenge, suggesting that CD40L may enhance the durability of RSV DNA vaccines.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12798640     DOI: 10.1016/s0264-410x(03)00119-1

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  9 in total

Review 1.  Respiratory syncytial virus (RSV) evades the human adaptive immune system by skewing the Th1/Th2 cytokine balance toward increased levels of Th2 cytokines and IgE, markers of allergy--a review.

Authors:  Yechiel Becker
Journal:  Virus Genes       Date:  2006-10       Impact factor: 2.332

2.  Multimeric soluble CD40 ligand and GITR ligand as adjuvants for human immunodeficiency virus DNA vaccines.

Authors:  Geoffrey W Stone; Suzanne Barzee; Victoria Snarsky; Kristin Kee; Celsa A Spina; Xiao-Fang Yu; Richard S Kornbluth
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

3.  CD40L-adjuvanted DNA/modified vaccinia virus Ankara simian immunodeficiency virus SIV239 vaccine enhances SIV-specific humoral and cellular immunity and improves protection against a heterologous SIVE660 mucosal challenge.

Authors:  Suefen Kwa; Lilin Lai; Sailaja Gangadhara; Mariam Siddiqui; Vinod B Pillai; Celia Labranche; Tianwei Yu; Bernard Moss; David C Montefiori; Harriet L Robinson; Pamela A Kozlowski; Rama Rao Amara
Journal:  J Virol       Date:  2014-06-11       Impact factor: 5.103

4.  Treatment with respiratory syncytial virus G glycoprotein monoclonal antibody or F(ab')2 components mediates reduced pulmonary inflammation in mice.

Authors:  Congrong Miao; Gertrud U Radu; Hayat Caidi; Ralph A Tripp; Larry J Anderson; Lia M Haynes
Journal:  J Gen Virol       Date:  2009-03-04       Impact factor: 3.891

5.  Incorporation of CD40 ligand into the envelope of pseudotyped single-cycle Simian immunodeficiency viruses enhances immunogenicity.

Authors:  Fan-ching Lin; Yue Peng; Leslie A Jones; Paulo H Verardi; Tilahun D Yilma
Journal:  J Virol       Date:  2008-11-26       Impact factor: 5.103

6.  Targeting CD40 enhances antibody- and CD8-mediated protection against respiratory syncytial virus infection.

Authors:  Abenaya Muralidharan; Marsha Russell; Louise Larocque; Caroline Gravel; Changgui Li; Wangxue Chen; Terry Cyr; Jessie R Lavoie; Aaron Farnsworth; Michael Rosu-Myles; Lisheng Wang; Xuguang Li
Journal:  Sci Rep       Date:  2018-11-09       Impact factor: 4.379

7.  T cell receptor signaling pathway and cytokine-cytokine receptor interaction affect the rehabilitation process after respiratory syncytial virus infection.

Authors:  Zuanhao Qian; Zhenglei Zhang; Yingying Wang
Journal:  PeerJ       Date:  2019-06-12       Impact factor: 2.984

Review 8.  Pulmonary DNA vaccination: concepts, possibilities and perspectives.

Authors:  Maytal Bivas-Benita; Tom H M Ottenhoff; Hans E Junginger; Gerrit Borchard
Journal:  J Control Release       Date:  2005-09-20       Impact factor: 9.776

9.  DNA Based Vaccine Expressing SARS-CoV-2 Spike-CD40L Fusion Protein Confers Protection Against Challenge in a Syrian Hamster Model.

Authors:  Levi A Tamming; Diana Duque; Anh Tran; Wanyue Zhang; Annabelle Pfeifle; Emmanuel Laryea; Jianguo Wu; Sathya N Thulasi Raman; Caroline Gravel; Marsha S Russell; Anwar M Hashem; Reem M Alsulaiman; Rowa Y Alhabbab; Jun Gao; David Safronetz; Jingxin Cao; Lisheng Wang; Wangxue Chen; Michael J W Johnston; Simon Sauve; Michael Rosu-Myles; Xuguang Li
Journal:  Front Immunol       Date:  2022-01-12       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.